JUL 08, 2021 8:40 AM PDT

Activating p53 May Boost Efficacy of Cancer Immunotherapy

WRITTEN BY: Annie Lennon

Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These findings, say researchers, could increase efficacy rates of immunotherapies to treat cancer. The study was published in Cancer Discovery by researchers at Karolinska Institutet in Sweden. 

For some time, scientists have known that p53 is able to prevent genome instability by silencing certain sequences in our genome known as endogenous retroviruses, elements of DNA that are inherited from viruses. 

Dubbed the ‘guardian of the genome’, the protein is thought to play a key role in inhibiting tumor growth. This comes as half of all tumors have mutations in the gene that codes for p53. Meanwhile, in many other tumors, p53 is disabled by another protein known as MDM2. 

The researchers behind the present study thus sought out to see whether pharmacologically activating p53 could affect the growth of cancer cells. To do so, they blocked MDM2 in mouse models with a substance known as ALRN-6924 from the US pharmaceutical company, Aileron Therapeutics. 

In doing so, the researchers noted that they were able to block MDM2 and activate p53. This then activated endogenous retroviruses which went on to trigger an antiviral response that boosted the production of interferons, signaling proteins that cause nearby cells to increase their anti-viral defenses. The same response was also noted in tumor samples from two patients taking part in the company’s clinical trials of ALRN-6924. 

"This shows that there are synergies that should be exploited between substances that block MDM2 and modern immunotherapies," says Galina Selivanova, lead author of the research, "A combination of these can be particularly important for patients who don't respond to immunotherapy."

Selivanova is currently researching whether a molecule known as APR-246, known as 'Eprenetapopt', can produce the same boost in interferons, and thus have the same potential to increase the efficacy of immunotherapy for patients with severe forms of cancer. 

 

Sources: Cancer DiscoveryEurekAlert

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAY 31, 2021
Immunology
Engineering Faster, More Agile T Cell Cancer Fighters
MAY 31, 2021
Engineering Faster, More Agile T Cell Cancer Fighters
Cell therapies use engineered T cells extracted from the patient’s own immune system to rally an attack on tumors. ...
JUN 22, 2021
Cancer
Evaluating adverse effects of induction therapy for neuroblastoma
JUN 22, 2021
Evaluating adverse effects of induction therapy for neuroblastoma
A study published in the Journal of Clinical Oncology reports an evaluation of the chemotherapy treatment given to child ...
JUL 13, 2021
Clinical & Molecular DX
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
JUL 13, 2021
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
Researchers have developed the first diagnostic “pen” that acts as a guide for surgeons, helping them distin ...
AUG 29, 2021
Cancer
Researchers Bioprint Deadly Brain Tumor with 3D Printer
AUG 29, 2021
Researchers Bioprint Deadly Brain Tumor with 3D Printer
Researchers have managed to print an entire active and viable glioblastoma tumor- the deadliest form of brain cancer- us ...
SEP 22, 2021
Cancer
Whole Genome Sequencing for Cancer Diagnostics
SEP 22, 2021
Whole Genome Sequencing for Cancer Diagnostics
The human genome consists of genetic material known as DNA.  We all have unique DNA sequences made up of four bases ...
OCT 21, 2021
Cancer
Exercise: A Secret Weapon to Combat Prostate Cancer?
OCT 21, 2021
Exercise: A Secret Weapon to Combat Prostate Cancer?
Exercise oncology is an evolving science that considers the addition of physical activity regimens to the treatment ...
Loading Comments...